Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Active Drug Controlled, Multi-center, Phase Ⅰ/Ⅲ Study to Determine the Efficacy and Safety of Meditoxin in Treatment of Crow's Feet Line

Next Previous
Trial Profile

A Randomized, Double-blind, Active Drug Controlled, Multi-center, Phase Ⅰ/Ⅲ Study to Determine the Efficacy and Safety of Meditoxin in Treatment of Crow's Feet Line

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Facial wrinkles
  • Focus Registrational; Therapeutic Use
  • Sponsors Medytox

    • Most Recent Events

    • 01 Aug 2021 Results published in the Journal of Dermatological Treatment
    • 13 Jul 2021 Primary endpoint (Percentage of Participants Achieving None or Mild on the Investigators Assessment of the Severity of Crows Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale(FWS)) has been met as per results published in the Journal of Dermatological Treatment
    • 25 Mar 2019 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top